Clinical Trial

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

Study acronym: CLEAR-HBV
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-13
Trial Details
NCT Number NCT07189377
Lead Sponsor University Health Network, Toronto
Conditions Hepatitis B Virus (HBV), Lung Transplant Recipient
Enrollment 20 participants
Start Date 2025-09-24
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-11-17